EGFR-Mutated NSCLC: Are Frontline Combinations the Future?

EGFR-Mutated NSCLC: Are Frontline Combinations the Future?

Episodes

Specialty:

All

Year:

All

EP. 1: Molecular Testing in Metastatic NSCLC

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 2: Metastatic NSCLC: The Role of Liquid Biopsy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 3: Molecular Testing Prior to Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 4: Approved Frontline TKIs for EGFR-Mutated Disease

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 5: The Use of TKIs in Patients With Brain Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 6: Data Updates From the GioTag Study

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 7: EGFR TKI Plus Chemotherapy Combination Strategy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 8: TKI Combination Clinical Trials: Practical Implications in US and UK

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 9: TKI Plus Antiangiogenic Combination Therapy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 10: RELAY Trial Regimen Adverse-Event Overview

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EP. 11: EGFR-Mutated NSCLC: Looking Ahead

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma